Market Place
Sourcing Support
Regeneron Pays $37M, $2B in Biobucks to Expand CytomX Deal
05 Jun 2026 //
FIERCE BIOTECH
Regeneron to Highlight Metabolic, Ophthalmic, Rare Disease at ADA
04 Jun 2026 //
GLOBENEWSWIRE
WHO Recommends Regeneron`s Ebola Antibody for Investigational Use
28 May 2026 //
GLOBENEWSWIRE
Regeneron Opens Hyderabad Center to Scale Operational Excellence
26 May 2026 //
EXPRESSPHARMA
Otarmeni Receives EMA Filing Acceptance for Genetic Hearing Loss
22 May 2026 //
GLOBENEWSWIRE
Lynozyfic Monotherapy Shows Deep Responses in AL Amyloidosis
21 May 2026 //
GLOBENEWSWIRE
Regeneron Slumps As Skin Cancer Treatment Fails Phase 3 Trial
18 May 2026 //
REUTERS
Regeneron reaches $125M Parabilis deal for hard-to-catch drug
18 May 2026 //
GLOBENEWSWIRE
Regeneron`s LAG-3 Combo Fails Late-Stage Melanoma Trial
17 May 2026 //
PRESS RELEASE
Over $7M Awarded to Young Scientists at 2026 Regeneron ISEF
15 May 2026 //
GLOBENEWSWIRE
Regeneron Makes Dow Jones Best-in-Class Index for 7th Year
08 May 2026 //
GLOBENEWSWIRE
Dupixent Improves Esophageal Function in EoE Phase 4 Trial
05 May 2026 //
GLOBENEWSWIRE
Regeneron Beats Quarterly Estimates On Strong Dupixent Demand
29 Apr 2026 //
REUTERS HEALTHCARE
Trump announces Drug Pricing Deal with Regeneron
27 Apr 2026 //
REUTERS
FDA Approves Regeneron`s First Gene Therapy for Hearing Loss
24 Apr 2026 //
FDA
FDA Approves Regeneron`s Gene Therapy for Hearing Loss
23 Apr 2026 //
BIOSPACE
Dupixent Approval For Children With Chronic Spontaneous Urticaria
22 Apr 2026 //
PRESS RELEASE
Cemdisiran Shows Deep Disease Control in gMG Phase 3 Trial
21 Apr 2026 //
PRESS RELEASE
Regeneron Announces Investor Conference Presentations
20 Apr 2026 //
GLOBENEWSWIRE
Telix And Regeneron Announce Strategic Radiopharma Collaboration
13 Apr 2026 //
GLOBENEWSWIRE
Dupixent Receives EU Approval For Young Children With CSU
13 Apr 2026 //
PRESS RELEASE
TriNetX & Regeneron to Share De-ID EHRs of 300M Patients
02 Apr 2026 //
PR NEWSWIRE
EYLEA HD Approved by FDA with Up to 5-Month Dosing for wAMD/DME
02 Apr 2026 //
GLOBENEWSWIRE
Regeneron Reports Q1 2026 Results, Hosts Earnings Call on Apr. 29
25 Mar 2026 //
GLOBENEWSWIRE
Dupixent Approved in Japan for Bullous Pemphigoid (BP)
24 Mar 2026 //
PRESS RELEASE
Gene Therapies For Hearing Loss Show Promise In Challenging Field
23 Mar 2026 //
BIOSPACE
Regeneron-Licensed Olatorepatide Shows Ph3 Obesity Data China
09 Mar 2026 //
GLOBENEWSWIRE
Regeneron Announces Investor Conference Presentation
05 Mar 2026 //
GLOBENEWSWIRE
EU CHMP Recommends Dupixent for Pediatric Chronic Urticaria
27 Feb 2026 //
PRESS RELEASE
Dupixent picks up 9th FDA approval
25 Feb 2026 //
PRESS RELEASE
Zydus Lifesciences launches Anyra, biosimilar of Aflibercept 2 mg
20 Feb 2026 //
EXPRESSPHARMA
FDA Grants Priority Review to Garetosmab for FOP
19 Feb 2026 //
GLOBENEWSWIRE
Ocular`s Ophthalmologic Version of Inlyta bests Eylea in ph. 3
17 Feb 2026 //
FIERCE PHARMA
Regeneron Announces Investor Conference Presentations
11 Feb 2026 //
GLOBENEWSWIRE
Regeneron Showcases Growing Immunology Pipeline at AAAAI
10 Feb 2026 //
GLOBENEWSWIRE
NICE Recommends Dupilumab For Severe CRSwNP In England & Wales
06 Feb 2026 //
PHARMIWEB
EYLEA HD Injection 8 mg Presentations at Angiogenesis 2026
02 Feb 2026 //
GLOBENEWSWIRE
Regeneron Bets Added Cholesterol Benefit Will Help Obesity Drug
30 Jan 2026 //
REUTERS
Regeneron Unveils 2025 Q4 & Full-Year Financial Results
30 Jan 2026 //
GLOBENEWSWIRE
Regeneron Faces Category Headwinds For Eye Disease Drug Eylea
30 Jan 2026 //
FIERCE PHARMA
Rising Stars: Catie Matthews On Navigating The AI Boom
21 Jan 2026 //
FIERCE PHARMA
BrightInsight Secures Multi-Million Investment For Ai Medication
20 Jan 2026 //
GLOBENEWSWIRE
Regeneron To Present Q4 2025 Financial Results, Host Conference
02 Jan 2026 //
GLOBENEWSWIRE
Dupixent Approved in Japan for Children Aged 6 to 11 Years
23 Dec 2025 //
GLOBENEWSWIRE
Alvotech, Teva Set U.S. Date For AVT06, Biosimilar To Eylea
19 Dec 2025 //
GLOBENEWSWIRE
Regeneron Rebounds Post Regulatory & Manufacturing Challenges
10 Dec 2025 //
BIOSPACE
ASH: Regeneron eyes simpler regimens to grow bispecifics` reach
08 Dec 2025 //
FIERCE PHARMA
Lynozyfic Shows Strong Responses in NDMM Patients
07 Dec 2025 //
GLOBENEWSWIRE
Regeneron Inks $150 M Pact with Gene Writer Tessera
01 Dec 2025 //
PRESS RELEASE
EU Approves Dupixent As First Targeted Drug For Chronic Urticaria
26 Nov 2025 //
PRESS RELEASE
EU Approves Libtayo as First CSCC Immunotherapy after Surgery
19 Nov 2025 //
GLOBENEWSWIRE
FDA Approves Eylea HD 8 mg for RVO Macular Edema
19 Nov 2025 //
GLOBENEWSWIRE
Regeneron To Invest $2B In New Saratoga Springs Production Plant
19 Nov 2025 //
FIERCE PHARMA
Regeneron Highlights Progress at American Society of Hematology
13 Nov 2025 //
GLOBENEWSWIRE
Regeneron Ph2 Factor XI Antibodies Show Antithrombotic Effect
08 Nov 2025 //
GLOBENEWSWIRE
Dupixent Study Meets Endpoints; sBLA Under FDA Priority Review
07 Nov 2025 //
PRESS RELEASE
Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins
07 Nov 2025 //
BUSINESSWIRE
Regeneron Announces Investor Conference Presentations
03 Nov 2025 //
GLOBENEWSWIRE
Dupixent Secures 2025 Prix Galien USA Best Biotech Product Award
31 Oct 2025 //
GLOBENEWSWIRE
Regeneron Pledges $1B+ For Modex Multispecific Antibodies
29 Oct 2025 //
FIERCE BIOTECH
